Perspectives
Is it time for erythropoietin use in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients?
Abstract
Anemia remains a frequent feature of hematologic malignancies. It was demonstrated that a significant proportion of multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) patients developed anemia at diagnosis, during chemotherapy or disease progression (1,2).